Skip to main content
. 2020 Apr 15;7(3):856–864. doi: 10.1002/ehf2.12694

Figure 1.

Figure 1

Study design of PARALLAX trial. Patients will be stratified according to therapy prior to study inclusion. Patients with ACEi therapy will be randomized to enalapril or sacubitril/valsartan; patients with ARB therapy will be randomized to valsartan or sacubitril/valsartan, and patients with neither therapy will be randomized to placebo or sacubitril/valsartan. *Patients in the ACEi and ARB strata must have a history of hypertension. ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; b.i.d., twice daily; RAAS, renin–angiotensin–aldosterone system; sac/val, sacubitril/valsartan.